Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Polaris Group has started dosing in a Phase 3 trial investigating cancer therapeutic pegylated arginine deiminase (ADI-PEG 20), in patients suffering from hepatocellular carcinoma (HCC).
Subscribe to our email newsletter
In the trial, around 600 patients are expected to be enrolled who have failed prior systemic therapy.
Further, the patients will be given weekly intramuscular injections of ADI-PEG 20 until disease progression.
The Phase 3 trial which aims at over all survival, is a double-blind, randomized, placebo-controlled trial.
Polaris Medical Affairs executive vice president John Bomalaski said they believe ADI-PEG 20 is a cancer therapeutic not only for HCC, but also other arginine-dependent cancers such as leukemia, lymphoma, sarcoma and prostate cancer.
"We look forward to continuing clinical development in all of these areas to understand the full potential for this therapeutic," Bomalaski said.